Table 1 Characteristics of stage III CC patients with low risk (T1-3 and N1) and high risk (T4 and/or N2) from our institution

Sex, N%

 Man

376 (59.3)

189 (57.6)

565 (58.7)

0.629

 Woman

258 (40.7)

139 (42.4)

397 (41.3)

Age, N%

 < 60

353 (55.7)

193 (58.8)

546 (56.8)

0.372

 ≥ 60

281 (44.3)

135 (41.2)

416 (43.2)

Laparoscopic surgery, N%

 No

80 (12.6)

62 (18.9)

142 (14.8)

0.012

 Yes

554 (87.4)

266 (81.1)

820 (85.2)

Tumor location, N%

 Right

170 (26.8)

99 (30.2)

269 (28.0)

0.289

 Left

464 (73.2)

229 (69.8)

693 (72.0)

pT stage, N%

 T1-3

634 (100.0)

188 (57.3)

822 (85.4)

 < 0.001

 T4

0 (0)

140 (42.7)

140 (14.6)

pN stage, N%

 N1

634 (100.0)

94 (28.7)

728 (75.7)

 < 0.001

 N2

0 (0)

234 (71.3)

234 (24.3)

No. LNs harvested, N%

 < 12

65 (10.3)

19 (5.8)

84 (8.7)

0.022

 ≥ 12

569 (89.7)

309 (94.2)

878 (91.3)

Histologic grade, N%

 Well/moderately

496 (78.2)

213 (64.9)

709 (73.7)

0.540

 Poorly

138 (21.8)

115 (35.1)

253 (26.3)

Histological type, N (%)

 Adenocarcinoma

540 (85.2)

250 (76.2)

790 (82.1)

0.001

 Mucinous or Signet ring cell

94 (14.8)

78 (23.8)

172 (17.9)

Lymphovascular Invasion, N%

 No

542 (85.5)

214 (65.2)

756 (78.6)

 < 0.001

 Yes

92 (14.5)

114 (34.8)

206 (21.4)

Perineural Invasion, N%

 No

505 (79.7)

219 (66.8)

724 (75.3)

 < 0.001

 Yes

129 (20.3)

109 (33.2)

238 (24.7)

CDX2, N%

 Positive

619 (97.6)

318 (97.0)

937 (97.4)

0.527

 Negative

15 (2.4)

10 (3.0)

25 (2.6)

MMR status, N%

 dMMR

54 (8.5)

33 (10.1)

87 (9.0)

0.477

 pMMR

580 (91.5)

295 (89.9)

875 (91.0)

Tumor deposits, N%

 No

402 (63.4)

180 (54.9)

582 (60.5)

0.012

 Yes

232 (36.6)

148 (45.1)

380 (39.5)

Timing of adjuvant therapy

 ≤ 6 weeks

610 (96.2)

321 (97.9)

931 (96.8)

0.184

 > 6 weeks

24 (3.8)

7 (2.1)

31 (3.2)

Adjuvant chemotherapy, N%

 3 months

373 (58.8)

135 (41.2)

508 (52.8)

 < 0.001

 3 to 6 months

261 (41.2)

193 (58.8)

454 (47.2)